Autor segons l'article: Pintó X; Masana L; Civeira F; Real J; Ibarretxe D; Candas B; Puzo J; Díaz JL; Amigó N; Esteban M; Valdivielso P
Departament: Medicina i Cirurgia
Autor/s de la URV: Ibarretxe Gerediaga, Daiana / Masana Marín, Luis
Paraules clau: Risk-factors Riesgo cardiovascular Remnant cholesterol Non-hdl cholesterol Low-density-lipoprotein Lipoproteins Lipoprotein particles Lipid-lowering therapy Ldl particle number Cardiovascular-disease Cardiovascular risk B-containing lipoproteins Apolipoprotein-b A-i resonancia magnética nuclear partículas lipoproteicas lipoproteins lipoproteínas lipoprotein particles cardiovascular risk
Resum: © 2020 The Authors The assessment and prevention of cardiovascular risk (CVR) that persists in patients with dyslipidaemia despite treatment and achievement of goals specific to the plasma concentration of cholesterol linked to low density (c-LDL) is a clinical challenge today, and suggests that conventional lipid biomarkers are insufficient for an accurate assessment of CVR. Apart from their lipid content, there are other lipid particle characteristics. The results of this study show that there are a number of lipoprotein compounds that determine atherogenic potential and its influence on the CVR. However, such additional characteristics cannot be analysed by the techniques commonly used in clinical laboratories. Nuclear Magnetic Resonance (NMR) is a technique that allows a detailed analysis to be made of the amount, composition, and size of lipoproteins, as well as providing more information about the detailed status of lipid metabolism and CVR in dyslipidaemia patients. In this article a group of lipidologists from the Spanish Society of Arteriosclerosis review the existing evidence on the atherogenic mechanisms of particles and describe the technical basis and interpretation of the profiles lipoproteins obtained by MRI, with special reference to the test available in Spain (Liposcale®). Likewise, the main patient profiles are defined as such that an analysis would provide information of greater clinical interest. These include: a) Suspected mismatch between lipid concentrations and particles, a common situation in diabetes, obesity, metabolic syndrome; b) Early atherothrombotic cardiovascular disease (ECVA) or recurrent without CVR factors to justify it; c) Lipid disorders, rare or complex, such as extreme concentrations of c-HDL, and d) Clinical situations where classical analytical techniques cannot be applied, such as very low c-LDL values.
Àrees temàtiques: Pharmacology (medical) Peripheral vascular disease Medicina iii Medicina i Cardiology and cardiovascular medicine
Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 15781879
Adreça de correu electrònic de l'autor: daiana.ibarretxe@urv.cat luis.masana@urv.cat
Identificador de l'autor: 0000-0002-0789-4954
Data d'alta del registre: 2024-08-24
Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
Referència a l'article segons font original: Clinica E Investigacion En Arteriosclerosis. 32 (5): 219-229
Referència de l'ítem segons les normes APA: Pintó X; Masana L; Civeira F; Real J; Ibarretxe D; Candas B; Puzo J; Díaz JL; Amigó N; Esteban M; Valdivielso P (2020). Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale®). Clinica E Investigacion En Arteriosclerosis, 32(5), 219-229. DOI: 10.1016/j.arteri.2020.04.004
Entitat: Universitat Rovira i Virgili
Any de publicació de la revista: 2020
Tipus de publicació: Journal Publications
Repositori URV